Abstract
Introduction: Hepatic steatosis is a frequent condition that afflicts, especially, obese and insulin-resistant patients. Diagnosis is usually made through imaging tests. Despite the high prevalence and risk of complications, there is no specific treatment approved, though a vast number of medications have been tested.
Objective: This study aimed to determine the efficacy of dipeptidyl peptidase IV inhibitors (i DPP- IV) in the treatment of NAFLD. Methods: We searched the electronic databases of the Cochrane Library, MEDLINE, EMBASE, and LILACS, as well as reference lists of the included studies and grey literature; 9 studies were selected for inclusion. Results: 7 studies were used for metanalysis for 3 outcomes. i DPP-IV showed an ALT-reducing power of MD -10.83 (95% CI 35.23 to 13.57) at 3 months and MD -9.27 (95% CI 10.92 to -7.62) at 6 months of intervention, as well as a reduction of hepatic steatosis via MRI of SMD 0.10 (95% CI 0.31 to 0.50); the overall incidence of adverse events was very low. The studies were considered of low and very low quality by the GRADE evaluation. Conclusion: Because of the overall poor quality of the studies and heterogeneity of the population analyzed, i DPP-IV did not show efficacy on inflammatory markers or fibrosis in patients with NAFLD.Keywords: Dipeptidyl-Peptidase IV inhibitors, fatty liver, steatohepatitis, type 2 diabetes mellitus, obesity, systematic review.
Current Diabetes Reviews
Title:Dipeptidyl Peptidase IV Inhibitors for Nonalcoholic Fatty Liver Disease - Systematic Review and Metanalysis
Volume: 17 Issue: 5
Author(s): Lucas Ribeiro dos Santos*, Marcio Luis Duarte, Maria Stella Peccin, Antônio Ricardo de Toledo Gagliardi and Tamara Melnik
Affiliation:
- Department of Internal Medicine, Faculty of Medical Sciences of Santos - Lusiada University, Santos/SP, Oswaldo Cruz St, 179 - Boqueirão, Santos - SP, 11015-300,Brazil
Keywords: Dipeptidyl-Peptidase IV inhibitors, fatty liver, steatohepatitis, type 2 diabetes mellitus, obesity, systematic review.
Abstract: Introduction: Hepatic steatosis is a frequent condition that afflicts, especially, obese and insulin-resistant patients. Diagnosis is usually made through imaging tests. Despite the high prevalence and risk of complications, there is no specific treatment approved, though a vast number of medications have been tested.
Objective: This study aimed to determine the efficacy of dipeptidyl peptidase IV inhibitors (i DPP- IV) in the treatment of NAFLD. Methods: We searched the electronic databases of the Cochrane Library, MEDLINE, EMBASE, and LILACS, as well as reference lists of the included studies and grey literature; 9 studies were selected for inclusion. Results: 7 studies were used for metanalysis for 3 outcomes. i DPP-IV showed an ALT-reducing power of MD -10.83 (95% CI 35.23 to 13.57) at 3 months and MD -9.27 (95% CI 10.92 to -7.62) at 6 months of intervention, as well as a reduction of hepatic steatosis via MRI of SMD 0.10 (95% CI 0.31 to 0.50); the overall incidence of adverse events was very low. The studies were considered of low and very low quality by the GRADE evaluation. Conclusion: Because of the overall poor quality of the studies and heterogeneity of the population analyzed, i DPP-IV did not show efficacy on inflammatory markers or fibrosis in patients with NAFLD.Export Options
About this article
Cite this article as:
dos Santos Ribeiro Lucas *, Duarte Luis Marcio , Peccin Stella Maria , Gagliardi Ricardo de Toledo Antônio and Melnik Tamara , Dipeptidyl Peptidase IV Inhibitors for Nonalcoholic Fatty Liver Disease - Systematic Review and Metanalysis, Current Diabetes Reviews 2021; 17 (5) : e101120187811 . https://dx.doi.org/10.2174/1573399816999201110195634
DOI https://dx.doi.org/10.2174/1573399816999201110195634 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with the increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to the microcirculatory disturbances and the reduced levels of endogenous growth factors. Delayed cutaneous wound healing is ...read more
Oxidative and inflammatory responses in the development of secondary diabetic complications
Diabetes, along with its associated secondary complications, represents a significant global health challenge, contributing significantly to morbidity and mortality. Unhealthy lifestyle habits, reduced physical activity, environmental pollutants, and stress are pivotal factors in the onset of diabetes, particularly type-2 diabetes. Poorly managed hyperglycemia can lead to various complications, including neuropathy, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry n-3 Fatty Acids: Role in Neurogenesis and Neuroplasticity
Current Medicinal Chemistry The Antioxidant Activity of Coumarins and Flavonoids
Mini-Reviews in Medicinal Chemistry Minifish mtDNA has Abundance of Repeat Sequences and Inefficient Replication In Vitro
Current Molecular Medicine Effect of Simvastatin use on Autonomic Function in Patients with End Stage Renal Disease
Cardiovascular & Hematological Disorders-Drug Targets Autoantibodies Associated with Psychiatric Disorders
Current Neurovascular Research Is Targeting microRNAs the Philosopher’s Stone for Vascular Disease?
Current Vascular Pharmacology In Silico Study of Flavonoids as DPP-4 and α-glucosidase Inhibitors
Letters in Drug Design & Discovery A Brief Review of circRNA Biogenesis, Detection, and Function
Current Genomics MR Imaging of Pancreatic Islets: Tracking Isolation, Transplantation and Function
Current Pharmaceutical Design Pharmacogenomics of Cardiovascular Complications in Diabetes and Obesity
Recent Patents on Biotechnology Role of Oxidative Stress in the Genesis of Atherosclerosis and Diabetes Mellitus: A Personal Look Back on 50 Years of Research
Current Aging Science Effect of Stilbene and Chalcone Scaffolds Incorporation in Clofibric Acid on PPARα Agonistic Activity
Medicinal Chemistry Case Series Describing an Outbreak of Highly Resistant Vancomycin Staphylococcus aureus (Possible VISA/VRSA) Infections in Orthopedic Related Procedures in Guatemala
Infectious Disorders - Drug Targets 18F-FDG-PET Correlates of Impulse Control Disorder in a Diabetic Patient
Endocrine, Metabolic & Immune Disorders - Drug Targets Glucagon-Like Peptide-1 Synthetic Analogs: New Therapeutic Agents for Use in the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Why are there Variations in the Responses of Glucagon-like Peptide-1 Agonists among the Type 2 Diabetic Patients?
Current Clinical Pharmacology Dyslipidaemia Related to Insulin Resistance and Cardiovascular Disease in South Asian and West African Populations
Current Pharmaceutical Design Protein Misfolding and Aggregation in Alzheimer's Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Applied Computational Techniques on Schizophrenia Using Genetic Mutations
Current Topics in Medicinal Chemistry